✦ LIBER ✦

The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer

Book ID: 122863450
Publisher: Elsevier Science
Year: 1993
Tongue: English
Weight: 151 KB
Volume: 10
Category: Article
ISSN: 0169-5002
DOI: 10.1016/0169-5002(93)90261-U

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The use of granulocyte colony-stimulatin

✍ Minoru Takada; Masahiro Fukuoka; Yutaka Ariyoshi; Kiyoyuki Furuse; Hisanobu Niit 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 548 KB

Schedule of granulocyte colony stimulati

Schedule of granulocyte colony stimulating factor (G-CSF) in dose intensive chemotherapy with cisplatin, etoposide, mitomycin in non-small cell lung cancer (NSCLC)

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 145 KB

The efficacy of MVP (mitomycin C, vindes

The efficacy of MVP (mitomycin C, vindesine and cisplatin) regimen as a salvage chemotherapy for non-small cell lung cancer

✍ Akiyama, Y; Kunitoh, H; Ohe, Y; Yamamoto, N; Kusaba, H; Watanabe, H; Sawada, M; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 104 KB

The limits of chemotherapy dose intensif

The limits of chemotherapy dose intensification using Granulocyte Colony Stimulating Factor alone in extensive small cell lung cancer

✍ Trillet-Lenoir, V.; Soler, P.; Arpin, D.; Bohas, C.; Riou, R.; Court-Fortune, I. 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 686 KB

Mitomycin C, vinblastine and cisplatin c

Mitomycin C, vinblastine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer

✍ Fumio Nomura; Kaoru Shimokata; Hiroshi Saito; Shuzo Sakai; Atsushi Watanabe; Hid 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 277 KB

Combination chemotherapy with mitomycin-

Combination chemotherapy with mitomycin-C, cisplatin, and vinblastine in the treatment of non-small-cell lung cancer

✍ Niell, Harvey B. ;Griffin, John P. 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB

The drug combination of mitomycin-C, cisplatin, and vinblastine was administered to 30 patients with stage III non-small-cell lung cancer. All patients had a performance status of 50% or greater, had evaluable disease, and had not received previous chemotherapy. The overall response rate was 37% wit